Page last updated: 2024-09-05

bn 80927 and Benign Neoplasms

bn 80927 has been researched along with Benign Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cendrós, JM; Cvitkovic, F; Delavault, P; Lesimple, T; Obach, R; Peraire, C; Perez-Mayoral, A; Principe, P; Pruñonosa, J; Soto, E; Trocóniz, IF	1

Trials

1 trial(s) available for bn 80927 and Benign Neoplasms

Article	Year
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome	2012

Article

Year

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2

Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Humans; Infusions, Intravenous; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutrophils; Tandem Mass Spectrometry; Treatment Outcome

2012